|
|
What: Luncheon with the Experts presented by the Carcinoid Cancer Foundation
Who: Ebrahim S. Delpassand, MD, FACNM is the featured guest
When: Thursday, April 8, 2021 from 12 noon to 1 pm, Eastern Time
Where: CCF’s Facebook Page, https://www.facebook.com/Carcinoid/. Just come to the page at noon and the program will begin. There is no need to register nor is there a special link.
| |
Ebrahim S. Delpassand, MD, FACNM, nuclear medicine specialist, is Chairman and Medical Director at Excel Diagnostics & Nuclear Oncology Center in Houston, Texas and founder, Chairman of the Board, and CEO of Radiomedix in Houston. Dr. Delpassand was formerly deputy chairman, associate professor, chief of clinical nuclear medicine and director of therapeutic nuclear medicine at MD Anderson Cancer Center in Houston, Texas. His prestigious credentials and extensive experience include the disciplines of therapeutic nuclear medicine, nuclear cardiology, monoclonal antibody imaging and positron emission tomography.
Among Dr. Delpassand’s research interests are peptide receptor radionuclide therapy and nuclear imaging for neuroendocrine tumors, including Cu-64 labeled DOTATATE, which was approved by the FDA in September 2020. Active neuroendocrine tumor clinical trials available at Excel are the Phase 1 Study of AlphaMedix™ in Adult Subjects With SSTR (+) NET, the Phase-II Study of Lu177DOTATOC in Adults With STTR(+)Pulmonary, Pheochromocytoma, Paraganglioma, Unknown Primary, Thymus NETs (PUTNET), or Any Other Non-.GEP-NET. (PUTNET), and Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients (COMPETE).
| |
|
|
|
|
|
|
|
